The significant revenue growth and raised guidance suggest strong commercial momentum for BRIUMVI. Traders should monitor upcoming clinical catalysts in 2026, including pivotal topline data for the ENHANCE trial (mid-year) and subcutaneous BRIUMVI (year-end 2026/1Q 2027), which could further validate the product's clinical utility and market potential.
Price Chart
Executive Summary
TG Therapeutics reported strong 2025 financial results with full-year revenue of $616.3 million, driven by 92% year-over-year growth in BRIUMVI U.S. net revenue to $594.1 million. The company raised its 2026 revenue guidance to $875-900 million and announced key clinical milestones ahead, including pivotal topline data readouts for its ENHANCE and subcutaneous BRIUMVI programs.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $616.3 million, up 88% YoY from $329.0 million in 2024
- BRIUMVI U.S. net revenue reached $594.1 million in 2025, representing 92% YoY growth
- Company raised 2026 total global revenue guidance to $875-900 million (including $825-850 million from BRIUMVI U.S. net revenue)
- Net income for 2025 was $447.2 million, compared to $23.4 million in 2024, driven by a $339.8 million non-recurring tax benefit
- Cash position was $199.5 million as of December 31, 2025
Financial Impact
Revenue grew 88% YoY to $616.3 million in 2025, with BRIUMVI U.S. sales up 92% to $594.1 million. 2026 revenue guidance implies 42-46% growth over 2025.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| BRIUMVI U.S. Net Revenue | $594.1M | +92.0% |
Risk Factors
- The substantial net income increase in 2025 was largely driven by a one-time $339.8 million tax benefit, not recurring operations
- Increased R&D and SG&A expenses reflect growing commercial and development investments, which could pressure margins if revenue growth slows
- Future revenue depends on successful execution of clinical trials and regulatory approvals for new indications and formulations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-005733 |
| Document: tgtx20251112_8k.htm | 0001437749-26-005733 |
| Document: 0001437749-26-005733-index-headers.html | 0001437749-26-005733 |
| Document: 0001437749-26-005733-index.html | 0001437749-26-005733 |
| Document: 0001437749-26-005733.txt | 0001437749-26-005733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $54.10 | awaiting T+60 | — | $56.44 (+4.33%) |
Aug 3, 2026 12w ago | 8-K | $46.17 $55.99 | ▲ +21.27% | ▲ +19.49% | $56.44 (+22.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $49.52 $55.74 | ▲ +12.56% | ▲ +9.30% | $56.44 (+13.97%) |
Jun 3, 2026 20w ago | 8-K | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $56.44 (+40.71%) |
Jun 3, 2026 20w ago | Press Release | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $56.44 (+40.71%) |
Jun 1, 2026 21w ago | Press Release | $37.41 $55.42 | ▲ +48.14% | ▲ +46.91% | $56.44 (+50.87%) |
May 27, 2026 21w ago | 8-K | $38.82 $54.27 | ▲ +39.80% | ▲ +38.06% | $56.44 (+45.39%) |
May 6, 2026 24w ago | 8-K | $41.97 $52.03 | ▲ +23.97% | ▲ +21.91% | $56.44 (+34.48%) |
Apr 30, 2026 25w ago | Press Release | $33.78 $55.75 | ▲ +65.04% | ▲ +61.93% | $56.44 (+67.08%) |
Apr 22, 2026 26w ago | Press Release | $38.31 $54.87 | ▲ +43.23% | ▲ +38.45% | $56.44 (+47.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers